Posted on 1/8/18
Alnylam Announces 2018 Corporate Goals
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc.(Nasdaq:ALNY), the leading RNAi therapeutics company, today announced its corporate goals for 2018. The goals focus on clinical and regulatory progress against . . .
Posted on 1/4/18
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration
TÜBINGEN, Germany & BOSTON & SAN DIEGO--(BUSINESS WIRE)--CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. . . .
Posted on 1/4/18
Bicycle Therapeutics Secures an Innovate UK Grant
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today . . .
Posted on 1/4/18
Pierre Fabre Enters Worldwide Licensing Agreement with Boston Pharmaceuticals
CASTRES, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pierre Fabre Pharmaceuticals (Pierre Fabre) and Boston Pharmaceuticals Inc. (Boston Pharmaceuticals) today announced they have entered into a worldwide licensing agreement . . .
Posted on 1/4/18
Bristol-Myers Squibb Leads $75M Series B For Personal Genome Diagnostics
Personal Genome Diagnostics Inc. (PGDx) today announced a $75 million Series B financing co-led by new investor Bristol-Myers Squibb and existing investor
Posted on 1/3/18
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January . . .
Posted on 1/3/18
OvaScience Announces Corporate Update
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScience (NASDAQ:OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today provided . . .
Posted on 1/3/18
HMR Program Ranked a No. 1 "Best Fast Weight-Loss Diet" for Third Consecutive Year
U.S. News & World Report has ranked HMR Weight Management Services (HMR) as a No. 1 Best Fast Weight Loss Diet for 2018. This is the . . .
Posted on 1/3/18
Biostage Closes $4.2 Million Private Placement
Biostage, Inc. (OTCQB: BSTG/BSTGD), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced . . .
Posted on 1/3/18
Altus Capital Partners Completes Tender Offer for MGC Diagnostics
WILTON, Conn.--(BUSINESS WIRE)--Altus Capital Partners, Inc., an investment firm focused on the North American manufacturing sector, announced the successful conclusion of the tender offer for all . . .
Posted on 1/3/18
Synspira Announces $3 Million Development Award from Cystic Fibrosis Foundation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, today announced that it has . . .
Posted on 1/3/18
Symbiotix Biotherapies Announces Process Development & Manufacturing Agreement with Paragon Bioservices
BOSTON--(BUSINESS WIRE)--Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel molecular therapeutics based on the human microbiome, today announced that it has entered into . . .
Posted on 1/3/18
3 Best Big Pharma Stocks to Buy for 2018
If you're expecting massive revenue growth for 2018 among big pharma stocks, think again. Despite hot new drugs for several major drugmakers, many of them also . . .
Posted on 1/3/18
3 Reasons Why 2018 Could Be Berkshire Hathaway's Best Year Yet
A new year brings new opportunity for Berkshire Hathaway (NYSE:BRK-A)(NYSE:BRK-B). It's my view that 2018 could be the company's best year yet, as three major trends . . .
Posted on 1/3/18
Should You Buy Bristol-Myers Squibb Stock in 2018?
Bristol-Myers Squibb (NYSE:BMY), in many ways, has led the immuno-oncology revolution with its game-changing checkpoint inhibitors Opdivo and Yervoy. However, the stock has lost a bit . . .
Posted on 1/3/18
Vericel Initiates Collaboration with Innovative Cellular Therapeutics
CAMBRIDGE, Mass. and SHANGHAI, China, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of . . .
Posted on 1/2/18
Horizon Technology Finance Provides $12 Million Venture Loan to Conventus Orthopaedics
Horizon Technology Finance Corporation (NASDAQ: HRZN), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in . . .
Posted on 1/2/18
AVEO Oncology Announces Refinanced Debt Facility
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today announced that it has completed the refinancing of its existing $20.0 million debt facility with Hercules Capital, Inc. and its . . .
Posted on 1/2/18
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), . . .
Posted on 1/2/18
Cue Biopharma Closes IPO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cue Biopharma™, Inc., (NASDAQ: CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to . . .
Posted on 1/2/18
Syros Announces Clinical Supply Agreement with Janssen
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that it has entered . . .
Posted on 1/2/18
Moderna to Provide Corporate and Pipeline Updates and Outline Strategic Priorities at 2018 J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines . . .
Posted on 12/31/17
Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the . . .
Posted on 12/31/17
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines . . .
Posted on 12/26/17
Biostage Announces Reverse Stock Split
Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced . . .
Boston
